Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma

Shah, Jennifer; Li, Gordon; Shaffer, J.; Azoulay, M.; Gibbs, Iris C.; Nagpal, Seema; Soltys, Scott G.

doi:10.1093/neuros/nyx115

Cited by 57 publications

(38 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the standard clinical dose of 0.1 mmol/kg, higher relaxivity may improve brain lesion depiction (4), as shown by crossover preclinical (31,32) and clinical (33,34) (22,23). With the continuous advances made in therapeutic strategies (24) such as stereotactic radiosurgery (25) and immunotherapies (26), the better imaging performance of gadopiclenol may improve patient follow-up in clinical practice (22,23). This greater imaging performance than that of marketed contrast agents was previously shown with a prototype of a high-relaxivity nonspecific GBCA, which was Table 4.…”

Section: High Longitudinal Relaxivity Applied To Improvement In the Dmentioning

confidence: 99%

Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model

et al. 2020

View full text Add to dashboard Cite

A fter brain metastasis, primary central nervous system (CNS) tumors are the most common malignant brain lesions (1); more than 40 000 are malignant, and 60% of all malignant CNS tumors are gliomas (2). With less than 10% of patients surviving at 5 years, early and accurate diagnosis of brain tumors is crucially important. Glioblastoma multiforme leads to 255 000 deaths per year worldwide (3). With gadolinium-based contrast agents (GBCA), contrast material-enhanced MRI is the first-line diagnostic approach for the detection and characterization of primary CNS tumors. This technique dramatically improves the diagnostic accuracy of brain MRI. Clinical management of brain tumors is highly dependent on the information provided by contrast-enhanced MRI, including the location, the size, and the precise border delineation of the lesion. Moreover, contrast material uptake is a surrogate marker for distinguishing between low-grade glioma (no contrast material uptake) and high-grade glioma (contrast enhancement). The common clinical dosage for GBCAs is 0.1 mmol per kilogram of body weight, which has a very high benefit-to-risk ratio (4). A higher GBCA dose leads to better brain lesion detection (5), but a concern is the dose-dependent long-term retention of gadolinium in tissue, especially after injection of less thermodynamically stable (ie, linear

show abstract

Section: High Longitudinal Relaxivity Applied To Improvement In the Dmentioning

confidence: 99%

Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To date, RN has been shown to develop following a wide range of radiation modalities, including SRS, whole-brain radiation therapy, brachytherapy, and proton beam therapy [5,23]. Reported incidences of RN following treatment with SRS have typically ranged from 4%-18% [5][6]22,24]. Furthermore, RN can arise regardless of initial therapy indication, as it has been reported following the irradiation of metastatic lesions, primary tumors, and arteriovenous malformations [5].…”

Section: Incidence Of Radiation Necrosismentioning

confidence: 99%

“…The prognosis for patients with RN is typically poor, with one study citing a median survival time of 30 months following the development of necrosis [3]. Incidence is highest following high-dose local radiation, such as stereotactic radiosurgery (SRS) or brachytherapy, with reported rates after SRS ranging from 4%-19% [4][5][6][7]. Numerous factors play a role in the potential for the development of RN, including radiation dose, fraction size, and subsequent administration of chemotherapy [8].…”

Section: Introductionmentioning

confidence: 99%

Radiation Necrosis in Intracranial Lesions

Munier

Ginalis

Patel

et al. 2020

Cureus

View full text Add to dashboard Cite

Radiation necrosis (RN) is a challenging potential complication of cranial radiation therapy. Believed to result from a complex interplay of vascular, glial, and immunologic factors, the exact mechanism of RN remains unclear. Patients who develop RN typically have a history of treatment with stereotactic radiation surgery or some other form of radiation-based therapy. The time frame for its development is variable, but it most often occurs one to three years following radiation therapy. Reported treatment doses capable of inducing radiation necrosis are variable, with higher doses per fraction more likely to induce RN. Furthermore, RN remains a challenging diagnosis for clinicians to make, as its presentation is often nonspecific and imaging studies might not clearly differentiate RN from tumor recurrence or pseudoprogression. RN is initially managed with corticosteroids, followed by bevacizumab, surgical resection, or laser interstitial thermal therapy if symptoms persist. In this review, we examine the literature regarding pathophysiology, incidence, imaging characteristics, and management strategies for radiation necrosis.

show abstract

“…3 Conventional therapy of GBM usually includes surgery, radiotherapy, chemotherapy and precise use of molecular targeted drugs. 4,5 The final lethality rate of GBM is high because of the characteristic of infiltrative growth, which makes it difficult to be resected completely and easy for tumor recurrence. 6 The poor prognosis is considered to be related to tumor recurrence and therapeutic resistance after tumor resection, and it is still a challenge for treating such intracranial tumors.…”

Section: Introductionmentioning

confidence: 99%

<p>Identification of Novel lncRNA Markers in Glioblastoma Multiforme and Their Clinical Significance: A Study Based on Multiple Sequencing Data</p>

Li¹,

Guo²

2020

OTT

View full text Add to dashboard Cite

Background: Long non-coding RNAs (lncRNAs) have been verified to have a vital role in the progression of glioblastoma multiforme (GBM). Our research was about to identify the potential lncRNAs which was closely associated with the pathogenesis and prognosis of glioblastoma multiforme. Methods: All RNA sequence profiling data from patients with GBM were obtained from The Genotype-Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA). Differently expressed genes identified from GBM and control samples were used to construct competing endogenous RNA (ceRNA) network and perform corresponding functional enrichment analysis. Univariate Cox regression followed by lasso regression and multivariate Cox was used to validate independent lncRNA factors and construct a risk prediction model. Quantitative polymerase chain reaction (qPCR) was performed to verify the expression levels of potential lncRNA biomarkers in human GBM clinical specimens. A gene set enrichment analysis (GSEA) was subsequently conducted to explore potential signaling pathways in which critical lncRNAs may be involved. Moreover, nomogram plot was applied based on our prediction model and significant clinical covariates to visualize the prognosis of GBM patients. Results: A total of 2023 differentially expressed genes (DEGs) including 56 lncRNAs, 1587 message RNAs (mRNAs) and 380 other RNAs were included. Based on predictive databases, 16lncRNAs, 32 microRNAs (miRNAs) and 99 mRNAs were used to construct a ceRNA network. Moreover, we performed a novel risk prediction model with 5 potential prognostic lncRNAs, in which 4 of them were newly identified in GBM, to predict the prognosis of GBM patients. Finally, a nomogram plot was constructed to illustrate the potential relationship between the prognosis of GBM and our risk prediction model and significant clinical covariates. Conclusion: In this study, we identified 4 novel potential lncRNA biomarkers and constructed a prediction model of GBM prognosis. A simple-to-use nomogram was provided for further clinical application.

show abstract

Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma

Cited by 57 publications

References 52 publications

Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model

Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model

Radiation Necrosis in Intracranial Lesions

<p>Identification of Novel lncRNA Markers in Glioblastoma Multiforme and Their Clinical Significance: A Study Based on Multiple Sequencing Data</p>

Contact Info

Product

Resources

About